Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 5 completed trials

    Completion Rate
    100%(5/5)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)

    Phase Distribution

    Phase 3
    1
    20%
    Phase 1
    4
    80%

    Phase Distribution

    4

    Early Stage

    0

    Mid Stage

    1

    Late Stage

    Phase Distribution5 total trials
    Phase 1Safety & dosage
    4(80.0%)
    Phase 3Large-scale testing
    1(20.0%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    100.0%

    5 of 5 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    5

    all time

    Status Distribution
    Completed(5)

    Detailed Status

    Completed5

    Development Timeline

    Analytics

    Development Status

    Total Trials
    5
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 14 (80.0%)
    Phase 31 (20.0%)

    Trials by Status

    completed5100%

    Recent Activity

    0 active trials
    Showing 5 of 5
    completedphase_3

    Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)

    NCT05716425
    completedphase_1

    A Bioequivalence Trial of Fasting Single Oral STI-1558 Capsule in Healthy Chinese Subjects

    NCT06044233
    completedphase_1

    A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558

    NCT05685719
    completedphase_1

    Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients

    NCT05523739
    completedphase_1

    Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers

    NCT05364840

    Clinical Trials (5)

    Showing 5 of 5 trials
    NCT05716425Phase 3

    Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)

    Completed
    NCT06044233Phase 1

    A Bioequivalence Trial of Fasting Single Oral STI-1558 Capsule in Healthy Chinese Subjects

    Completed
    NCT05685719Phase 1

    A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558

    Completed
    NCT05523739Phase 1

    Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients

    Completed
    NCT05364840Phase 1

    Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers

    Completed

    All 5 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    5